Evidence map›Paper›PMID 26469961›Full record

ArticleCell death & disease2015

HOI-02 induces apoptosis and G2-M arrest in esophageal cancer mediated by ROS.

C Zhang, K Liu, K Yao, K Reddy, Y Zhang, Y Fu, G Yang, T A Zykova, S H Shin, H Li and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

C ZhangDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
K LiuDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
K YaoDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
K ReddyDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
Y ZhangDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
Y FuDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
G YangDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
T A ZykovaDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
S H ShinDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
H LiDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
J RyuDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
Y-N JiangDepartment of Pathology and Pathophysiology, Basic Medical College, Zhengzhou University, Zhengzhou, China.
X YinDepartment of Pathology and Pathophysiology, Basic Medical College, Zhengzhou University, Zhengzhou, China.
W MaDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
A M BodeDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
Z DongDepartment of Pathology and Pathophysiology, Basic Medical College, Zhengzhou University, Zhengzhou, China.
Z DongDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN, USA.
Hormel (United States) · USUniversity of Minnesota · USZhengzhou University · CNChina-US (Henan) Hormel Cancer Institute · CN

Funding

Developing new ornithine decarboxylase inhibitors to prevent skin & colon cancerR01CA166011 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2017
$1.6M
Anticarcinogenic Mechanisms of Tea ConstituentsR37CA081064 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2008 to 2012
$1.5M
Molecular Mechanisms and Targets of Soy Compounds in the Prevention of Colon CancR21CA172457 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2014
$327k
NCI NIH HHS CA166011NCI NIH HHS CA172457NCI NIH HHS R01 CA166011NCI NIH HHS R21 CA172457NCI NIH HHS R37 CA081064NCI NIH HHS R37CA081064
6 · The paper itself

Abstract

Reactive oxygen species (ROS) are chemically reactive molecules that perform essential functions in living organisms. Accumulating evidence suggests that many types of cancer cells exhibit elevated levels of ROS. Conversely, generation of ROS has become an effective method to kill cancer cells. (E)-3-hydroxy-3-(4-(4-nitrophenyl)-2-oxobut-3-en-1-yl) indolin-2-one, which is an NO2 group-containing compound designated herein as HOI-02, generated ROS and, in a dose-dependent manner, decreased esophageal cancer cell viability and inhibited anchorage-independent growth, followed by apoptosis and G2-M arrest. Moreover, results of an in vivo study using a patient-derived xenograft mouse model showed that HOI-02 treatment suppressed the growth of esophageal tumors, without affecting the body weight of mice. The expression of Ki-67 was significantly decreased with HOI-02 treatment. In addition, the phosphorylation of c-Jun, and expression of p21, cleaved caspase 3, and DCFH-DA were increased in the HOI-02-treated group compared with the untreated control group. In contrast, treatment of cells with (E)-3-(4-(4-aminophenyl)-2-oxobut-3-en-1-yl)-3-hydroxyindolin-2-one, which is an NH2 group-containing compound designated herein as HOI-11, had no effect. Overall, we identified HOI-02 as an effective NO2 group-containing compound that was an effective therapeutic or preventive agent against esophageal cancer cell growth.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCaspase 3Cell Line, TumorCell ProliferationCell SurvivalCyclin-Dependent Kinase Inhibitor p21Esophageal NeoplasmsG2 Phase Cell Cycle CheckpointsHumansIndolesMaleMice, SCIDMiddle AgedNitrobenzenes3-hydroxy-3-(4-(4-nitrophenyl)-2-oxobut-3-en-1-yl)indolin-2-oneAntineoplastic AgentsCASP3 protein, humanCaspase 3CDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21IndolesNitrobenzenesReactive Oxygen SpeciesTranscription Factor AP-1

Identifiers

PMID26469961
PMCPMC4632281
OpenAlexW2422262827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.